Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as REGN2222(SAR438584)
REGN2222 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Reference Drug | EXPERIMENTAL | REGN2222 Reference Formulation |
| Test Drug | EXPERIMENTAL | REGN2222 Test Formulation |
| Cohort 1 | EXPERIMENTAL | Dosing regimen 1 |
| Cohort 2 | EXPERIMENTAL | Dosing regimen 2 |
| Cohort 3 | EXPERIMENTAL | Dosing regimen 3 |
| Cohort 4 | EXPERIMENTAL | Dosing regimen 4 |
| Cohort 5 | EXPERIMENTAL | Dosing regimen 5 |
| Name | Type | Description |
|---|---|---|
| REGN2222 | DRUG | - |
| REGN2222(SAR438584) | DRUG | - |
| placebo | DRUG | - |
Key Inclusion Criteria: 1. Healthy man or woman aged 18 to 60 years 2. Body weight between 50.0 kg and 95.0 kg, inclusive 3. Willing and able to comply with clinic visits and study-related procedures 4. Provide signed informed consent Key Exclusion Criteria: 1. Hemoglobin not within normal limits...
REGN2222 is an investigational small molecule developed by Regeneron Pharmaceuticals, Inc. (ticker REGN) that targets respiratory syncytial virus (RSV). It has been studied in Phase 1 clinical trials in healthy adult volunteers. No approved indication has been established for REGN2222.
REGN2222 targets respiratory syncytial virus (RSV), a virus that causes respiratory infections. Its target class is viral. The compound is a small molecule designed to act against RSV. Both completed Phase 1 studies enrolled healthy volunteers rather than patients with active RSV infection.
REGN2222 is developed by Regeneron Pharmaceuticals, Inc., which trades under the ticker REGN. The alternative name REGN2222(SAR438584) reflects the same asset, and the SAR prefix indicates a Sanofi collaboration naming convention used for this compound.
REGN2222 is in Phase 1 development. Two Phase 1 trials have been completed, and no active trials are ongoing. The drug is investigational and has not been approved by the FDA for any indication. Both completed studies were conducted in healthy adult volunteers in the United States.
REGN2222 has been evaluated in two completed Phase 1 trials. NCT02121080 studied the safety and tolerability of REGN2222(SAR438584) in 132 healthy adult volunteers. NCT02828397 compared blood concentrations of two formulations of REGN2222 in 28 healthy subjects. Both trials were randomized, double-blind, and controlled, enrolling 160 participants total.
Yes, REGN2222 and SAR438584 refer to the same investigational compound, written together as REGN2222(SAR438584). REGN2222 is the Regeneron designation, while SAR438584 is the corresponding Sanofi code. Both names appear in the Phase 1 trial NCT02121080, which studied the drug in healthy adult volunteers.